Molecular Insight Pharmaceuticals Information

As of January 22, 2013, Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals. Molecular Insight Pharmaceuticals, Inc. develops therapeutic radiopharmaceuticals and molecular imaging agents for use in oncology and cardiology. The company targets the development of a small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a systemic radiotherapy for relapsed and metastatic prostate cancer. Its products include technetium Tc 99m trofolastat, a clinical-stage molecular imaging agent for patients with metastatic prostate cancer; and 131I-MIP-1095, a prostate cancer therapy for systemic delivery of radiotherapy.